These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure. Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753 [No Abstract] [Full Text] [Related]
6. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Ostergren JB J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570 [TBL] [Abstract][Full Text] [Related]
14. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure. Hennekens CH; Kowalczykowski M; Hollar D J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293 [TBL] [Abstract][Full Text] [Related]
15. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. McKelvie RS J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580 [TBL] [Abstract][Full Text] [Related]
19. Candesartan and heart failure: the allure of CHARM. White HD Lancet; 2003 Sep; 362(9386):754-5. PubMed ID: 13678864 [No Abstract] [Full Text] [Related]